Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 4Phase NA 2Phase EARLY_PHASE1 2Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 1Neoplasms 1Head and Neck Neoplasms 1Depressive Disorder, Major 1Chronic Pain 1Cancer Pain 1Acute Pain 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × Ketamine × Clear all
NCT03146806 2021-09-09

Intranasal (NAS) Ketamine for Cancer Pain

Emory University

Phase 1/2 Completed
10 enrolled 26 charts

Cancer Pain, Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡